GlobeNewswire by notified

Pioneering Tech Authority to Address INVENTURE$ 2023 Conference

Share

The Metaverse and how it will revolutionize everything

CALGARY, Alberta, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Matthew Ball, an international expert on the metaverse will be a featured keynote at INVENTURE$ 2023 in Calgary, May 31-June 2. He will take center stage on Wednesday, May 31, 2023.

The metaverse is the key battleground in Big Tech, most notably with Mark Zuckerberg’s announcement that Facebook would transform into a “metaverse company” and would henceforth be named Meta. Jensen Huang, founder of Nvidia, also one of the ten largest public companies in the world by market capitalization, believes the metaverse economy will ultimately exceed that of the real world. Tim Sweeney of Epic Games, creator of Fortnite, has warned that “if one central company gains control of [the metaverse], they will become more powerful than any government and can be God-on-earth.”

Mathew Ball will cover the definition of the metaverse, explaining how it will be realized. He will reveal what it will mean for the automotive, healthcare, education industries, among many others—even sex work. Ball will address. the governance and philosophies of the metaverse, the various battles and wars that will be fought over it, and how independent users, developers, and voters can shape its development.

Ball is the Managing Partner of EpyllionCo, which operates an early-stage venture fund, as well as a corporate and venture advisory arm. He is a Venture Partner at the famed gaming investment fund Makers Fund, Industry Advisor to private equity giant KKR, and a co-founder of Ball Metaverse Research Partners, which creates and maintains the index behind the world’s first Metaverse ETF, the Roundhill Ball Metaverse ETF, which can be found on the New York Stock Exchange (Ticker: $METV). Ball is also a contributor to The Economist, a producer behind Genvid Technologies’ Rival Peak, a more than three month-long interactive video event that was played by millions and is an advisor to start-ups such as Dapper Labs, The Athletic, and more.

“The metaverse is the next frontier for life in the twenty first century. Understanding how we can navigate this virtual world will create tremendous opportunity,” says Alberta Innovates CEO Laura Kilcrease.” Matthew Ball brings incredible depth to the metaverse conversation and I can’t wait to hear what he presents at INVENTURE$.”

INVENTURE$ is a global innovation experience hosted by Alberta Innovates to bring together the world’s brightest minds, angels, venture capitalists and industry leaders. Launched in 2018, INVENTURE$ is gaining global interest as the place to discover new technologies, talent, capital, customers and markets.

Tickets are available for $899 at https://inventurescanada.com/


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ETC’s Commercial/Industrial Units Awarded Three Contracts Totaling $15.9 Million6.5.2024 22:15:00 CEST | Press release

SOUTHAMPTON, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation’s (OTC Pink: ETCC) (“ETC” or the “Company”) Sterilization Systems Group announced it has been awarded $13.9 million in contracts from two multi-national medical device manufacturers. The contracts include four, sixteen pallet ethylene oxide (“EO”) sterilization system chambers with related conveyer systems, and a large capacity vacuum drying chamber with preconditioning. “These contracts reflect ETC Sterilization Systems Group’s dedication to innovation in our mechanical designs, control systems and software expertise to meet the challenging requirements of this market,” states Eric Hunnicutt, ETC Director of EO Sterilizer Sales. ETC’s Sterilization Systems Group offers Steam and Ethylene Oxide (“EO”) Sterilizer Systems, Vacuum Dryers, Software Systems, and project management services to the Medical Device, Pharmaceutical, Biotechnology, and Life Science industries. ETC’s systems are specially design

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC6.5.2024 22:05:00 CEST | Press release

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for the bispecific antibody zenocutuzumab (Zeno) in patients with neuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancer. “FDA acceptance of our first BLA represents an important achievement for Merus and an important potential treatment opportunity for patients with NRG1+ cancer, a disease with poor prognosis and high unmet need,” said Dr. Andrew Joe, Chief Medical Officer at Merus. “Zenocutuzumab has the potential to be the first and only targeted therapy for patients with NRG1+ lung and

Nokia Corporation: Repurchase of own shares on 06.05.20246.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 06 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 06.05.2024 Espoo, Finland – On 06 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL385,6823.45CEUX--BATE--AQEU--TQEX--Total385,6823.45 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Trading in Novo Nordisk shares by board members, executives and associated persons6.5.2024 21:02:16 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a) Name of the Board member/Executive/Associated Person Novo Holdings A/S, associated to Kasim Kutay 2 Reason for the notification a) Position/status Member of the Board of Directors b) Initial notification/Amendment Initial notification 3 Details of the issuer a) Name Novo Nordisk A&S b) LEI 549300DAQ1CVT6CXN342

Novo Nordisk A/S - share repurchase programme6.5.2024 20:44:48 CEST | Press release

Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 2.2 billion in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 7 May 2024 and ending on 5 August 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our

HiddenA line styled icon from Orion Icon Library.Eye